Holen Sie sich die Stockscreener-App
21.82
1.56%
-0.365
Schlusskurs vom Vortag:
$22.18
Offen:
$21.99
24-Stunden-Volumen:
1.63M
Relative Volume:
0.31
Marktkapitalisierung:
$10.85B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$205.00M
KGV:
54.54
EPS:
0.4
Netto-Cashflow:
$372.00M
1W Leistung:
-6.33%
1M Leistung:
-2.96%
6M Leistung:
+62.46%
1J Leistung:
+78.24%
1-Tages-Spanne:
$21.72
$22.14
1-Wochen-Bereich:
$21.72
$23.52
52-Wochen-Spanne:
$8.02
$23.70
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
450 ELANCO CIRCLE, INDIANAPOLIS
Vergleichen Sie ELAN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
21.83 | 11.02B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
121.16 | 54.02B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.34 | 45.21B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.58 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.11 | 31.93B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
481.31 | 20.71B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Hochstufung | Argus | Hold → Buy |
| 2025-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-19 | Eingeleitet | Jefferies | Buy |
| 2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Sell |
| 2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-28 | Herabstufung | Stifel | Buy → Hold |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Eingeleitet | Stifel | Buy |
| 2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Herabstufung | Argus | Buy → Hold |
| 2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
| 2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-08-04 | Fortgesetzt | Goldman | Buy |
| 2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Eingeleitet | Barclays | Overweight |
| 2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-23 | Eingeleitet | UBS | Sell |
| 2019-01-15 | Eingeleitet | Argus | Buy |
| 2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
Why retail traders accumulate Elanco Animal Health Incorporated stockWeekly Trade Summary & Consistent Profit Focused Trading Strategies - Newser
Aquatic Veterinary Market Set to See Booming Growth 2025-2032 - openPR.com
Is Elanco Animal Health Incorporated stock vulnerable to rate hikesTrade Analysis Summary & Capital Efficiency Focused Strategies - Newser
Will Elanco Animal Health Incorporated stock beat international competitionMarket Trend Review & Expert-Curated Trade Recommendations - Newser
Will Elanco Animal Health Incorporated (5EA) stock outperform benchmarksMarket Movers & Daily Volume Surge Trade Alerts - Newser
What downside risks could hit Elanco Animal Health Incorporated stock2025 Market Outlook & Reliable Breakout Forecasts - Newser
Can Elanco Animal Health Incorporated (5EA) stock retain market dominance - Newser
Can Elanco Animal Health Incorporated (5EA) stock deliver consistent EPS growthJuly 2025 Action & Momentum Based Trading Ideas - Newser
Will Elanco Animal Health Incorporated (5EA) stock boost dividends furtherTake Profit & Low Drawdown Investment Ideas - Newser
Is Elanco Animal Health Incorporated stock vulnerable to regulatory risksLong Setup & Weekly Watchlist of Top Performers - Newser
mRNA Vaccines for Animals Market Forecast 2025-2032: Emerging - openPR.com
Elanco Animal Health (NYSE:ELAN) Stock Steady on Sector Review - Kalkine Media
Elanco Animal Health (ELAN) Is Up 8.6% After FDA Clears First Cat Screwworm Treatment – Has the Bull Case Changed? - Yahoo Finance
Can Elanco Animal Health Incorporated stock beat market expectations this quarterJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Aug Decliners: Is Elanco Animal Health Incorporated stock dividend yield sustainableIPO Watch & High Return Trade Guides - BỘ NỘI VỤ
Elanco Animal Health Announces $245M Stock-For-Stock Acquisition Of Aratana Therapeutics - AOL.com
Elanco executive appointed as Neurizon’s board observer By Investing.com - Investing.com Canada
Elanco executive appointed as Neurizon's Board Observer - Yahoo Finance
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know - Finviz
Top Animal Health Stocks: Elanco Leads with Innovation, Zoetis Faces Headwinds - Investing.com Canada
Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4) - Quantisnow
Elanco (ELAN) Gains FDA Emergency Use Authorization for Credelio CAT - GuruFocus
Elanco (ELAN) Upgraded to Overweight, Targets $27 Per Share - GuruFocus
Elanco's Credelio CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats - Finviz
Elanco (ELAN) Gains FDA Emergency Use Approval for Cat Treatment - GuruFocus
Elanco stock rises after FDA emergency authorization for cat screwworm treatment - Investing.com Canada
Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats - Reuters
Elanco wins Overweight rating, Zoetis Sector Weight as KeyBanc reviews animal health space - Seeking Alpha
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats - Nasdaq
Elanco Animal Health Stock Is Undervalued: AnalystElanco Animal Health (NYSE:ELAN) - Benzinga
Elanco Animal Health rises as KeyBanc joins bull camp - TradingView
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
How Elanco Animal Health Incorporated stock moves on employment dataJuly 2025 Short Interest & AI Powered Market Entry Strategies - newser.com
Keybanc Initiates Coverage on ELAN with Overweight Rating and $2 - GuruFocus
Elanco to Participate in the Upcoming Investor Conferences - Investing News Network
Elanco's Credelio CAT gets FDA Emergency Use Authorization (ELAN) - Seeking Alpha
KeyBanc initiates Elanco Animal Health stock with Overweight rating By Investing.com - Investing.com Canada
Elanco (ELAN) Receives Overweight Rating with Promising Growth P - GuruFocus
Elanco Animal Health (ELAN): Evaluating Valuation After Strong Q3 Earnings and Bullish Analyst Upgrades - Yahoo Finance
Can Elanco Animal Health Incorporated stock weather global recessionEarnings Risk Report & Safe Swing Trade Setup Alerts - newser.com
Elanco Animal Health (NYSE:ELAN) Upgraded by Argus to "Buy" Rating - MarketBeat
Primecap Management Co. CA Buys 1,543,279 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Can Elanco Animal Health Incorporated stock deliver surprise earnings beatJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Is Elanco Animal Health Incorporated (5EA) stock a momentum leaderLayoff News & Stock Timing and Entry Methods - newser.com
Is Elanco Animal Health Incorporated stock positioned for secular growthWeekly Profit Recap & AI Driven Price Predictions - newser.com
Will Elanco Animal Health Incorporated stock benefit from sector leadershipInflation Watch & Consistent Return Investment Signals - newser.com
How Elanco Animal Health Incorporated stock reacts to global recession fearsJuly 2025 Closing Moves & Weekly Setup with ROI Potential - newser.com
Can Elanco Animal Health Incorporated stock surprise with earnings upsideEntry Point & High Conviction Trade Alerts - newser.com
Will Elanco Animal Health Incorporated stock deliver better than expected guidanceMarket Volume Report & AI Enhanced Trading Alerts - newser.com
Will Elanco Animal Health Incorporated (5EA) stock benefit from Fed rate cuts2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - newser.com
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Elanco Animal Health Inc-Aktie (ELAN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kurzius Lawrence Erik | Director |
Mar 07 '25 |
Buy |
10.90 |
10,000 |
109,000 |
101,459 |
| Kurzius Lawrence Erik | Director |
Mar 11 '25 |
Buy |
10.20 |
10,000 |
102,000 |
111,459 |
| HOOVER R DAVID | Director |
Mar 05 '25 |
Buy |
10.90 |
25,000 |
272,558 |
210,000 |
0.11%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):